Pharmacologic class (EPC) · 13 drug pages

Prostaglandin analog: adverse event reports filed with FDA

51,210 reports list a drug in this class as a suspect or interacting product, 2004–2026.

Read first · FDA's statement on these data

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product. openFDA, FDA

FDA adds: "There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event." The information in these reports "cannot be used to estimate the incidence of these events."

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

51,210
reports across the class: 0.3% of all reports; 1,291
reports, 12 months to June 2026: 1,214 in the 12 months before; 27.8%
marked serious by the reporter: 57.4% across all reports; 13
drugs with a page: brand and generic names counted separately

Prostaglandin analog is a pharmacologic class (an FDA Established Pharmacologic Class) with 13 drug pages on this site. Together those drugs are listed as a suspect or interacting product in 51,210 adverse event reports received by FDA, 0.3% of the database, from January 2004 to June 2026.

1,291 reports arrived in the 12 months to June 2026, close to the 1,214 of the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. 27.8% of the class's reports are marked serious, 2.5% record death among the outcomes and 4.5% record hospitalisation, as reported.

Across the class the reactions recorded most often are treatment failure (21.4%), drug ineffective (12.6%) and eye irritation (8.4%). The class median share shown beside each term is the middle value across the member drugs; it is the comparison used on every drug page in this class.

The members table is ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Drugs in the class

Drug	Name type	Reports	Latest 12 months	Marked serious	Top term recorded
Latanoprost	generic	12,387	545	19.8%	Treatment failure
LumiganBimatoprost	brand	9,203	223	15.3%	Treatment failure
XalatanLatanoprost	brand	9,038	25	76.6%	Intraocular pressure increased
LatisseBimatoprost	brand	8,743	116	2%	Drug ineffective
Travatan ZTravoprost	brand	3,937	108	22.3%	Treatment failure
ZioptanTafluprost	brand	1,864	10	25.5%	Ocular hyperaemia
Travoprost	generic	1,633	75	18.2%	Treatment failure
CaverjectAlprostadil	brand	1,198	10	42.8%	Drug ineffective
Bimatoprost	generic	775	57	37%	Drug ineffective
Alprostadil	generic	681	24	89.6%	Off label use
XelprosLatanoprost	brand	610	8	18.2%	Eye irritation
RocklatanNetarsudil and latanoprost ophthalmic solution, 0.02%/0.005%	brand	607	90	10%	Ocular hyperaemia
Latanoprost ophthalmic solution 0.005%	generic	534	0	12.4%	Eye irritation

Ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Reports by month, five years

FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

Reactions recorded across the class

share of class reports recording the termmedian drug in the class

Treatment failurethe treatment did not work21.4%10,938
Drug ineffectivethe medicine did not work as expected12.6%6,459
Eye irritationeye irritation8.4%4,310
Ocular hyperaemiaa red eye8%4,109
Intraocular pressure increasedraised pressure in the eye4.5%2,296
Eye paineye pain4.3%2,185
Eye pruritus4.2%2,160
Hypersensitivityan allergic-type reaction3.7%1,885
Vision blurredblurred vision3.3%1,673
Madarosis2.8%1,429
Cataractclouding of the eye lens2.5%1,258
Dry eyedry eye2.4%1,223
Erythema of eyelid2.1%1,101
Visual impairmentreduced vision2.1%1,066
Headachehead pain2%1,020
Eye swellinga swollen eye1.9%975
Glaucomaraised pressure in the eye1.9%952
Incorrect dose administeredthe wrong dose was given1.5%770
Deaththe patient died; cause not stated by this term1.5%757
Eye disorder1.4%737
Visual acuity reducedreduced sharpness of vision1.4%729
Product quality issuea problem with the product itself1.4%725
Wrong technique in product usage processthe product was used in the wrong way1.4%722
Drug hypersensitivityan allergic-type reaction to a medicine1.4%715
Off label useused for a purpose or in a way not on the label1.4%701

Solid bar: share of all class reports. Hollow bar: the median share across the 13 member drugs, the reference used on each member's page. One report can record several terms.

Outcomes, patients and reporters

Outcomes recorded

Death2.5%1,286

Life-threatening0.5%253

Hospitalisation (initial or prolonged)4.5%2,310

Disability1.1%543

Congenital anomaly0.1%36

Other serious23%11,781

Not serious72.2%36,957

Patient age

Under 20.2%122

2 to 110.2%79

12 to 170.1%40

18 to 443.1%1,587

45 to 649.7%4,962

65 to 748.4%4,285

75 and over11.8%6,031

Age not given66.6%34,104

Who reported

Physician11.9%6,075

Pharmacist2.8%1,418

Other health professional12.9%6,593

Lawyer0%21

Consumer or non-health professional68.8%35,209

Not given3.7%1,894

Grey bar: all 20,646,523 reports in the database. Outcome flags are as the reporter set them and are not verified by FDA.

Questions about Prostaglandin analog reports

Which drugs are in the Prostaglandin analog class on this site?

Latanoprost, Lumigan, Xalatan, Latisse, Travatan Z and Zioptan and 7 more. Class membership comes from the pharmacologic class (EPC) on the drug's FDA label.

How many reports does the class have?

51,210 reports through June 2026, 1,291 of them in the latest 12 months. A report listing two drugs of the class counts once for each.

What reactions are recorded most often?

treatment failure (21.4%), drug ineffective (12.6%), eye irritation (8.4%), ocular hyperaemia (8%) and intraocular pressure increased (4.5%).

Can the members table be used to rank the drugs?

No. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic." Drugs differ in how many people take them, in the conditions they treat, in time on the market and in how diligently reports are collected.

How do I report an adverse event?

Through FDA MedWatch (Form FDA 3500, or 1-800-FDA-1088) or to the manufacturer. See the guide on how to report.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A class is the Established Pharmacologic Class most often attached to a drug's reports by openFDA's label harmonisation, or from the NDC Directory where reports carry none. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.

Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.